ALBUTEROL SULFATE syrup United States - English - NLM (National Library of Medicine)

albuterol sulfate syrup

atlantic biologicals corp. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2 mg in 5 ml - albuterol sulfate syrup is indicated for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease. albuterol sulfate syrup is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components.

ALBUTEROL SULFATE tablet United States - English - NLM (National Library of Medicine)

albuterol sulfate tablet

bryant ranch prepack - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2 mg - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.

ALBUTEROL SULFATE solution United States - English - NLM (National Library of Medicine)

albuterol sulfate solution

a-s medication solutions - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2.5 mg in 3 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm. albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components. albuterol sulfate inhalation solution 0.083% 2 note: this is a unit-dose vial. no dilution is required. read complete instructions carefully before using. - remove the vial from the foil pouch. - twist the cap completely off the vial and squeeze the contents into the nebulizer reservoir (figure 1). - connect the nebulizer reservoir to the mouthpiece or face mask (figure 2). - connect the nebulizer to the compressor. - sit in a comfortable, upright position; place the mouthpiece in your mouth (figure 3) (or put on the face mask); and turn on the compressor. - breathe as calmly, deeply and evenly as possible until no more mist is formed in the nebulizer chamber (about 5 to 15 minu

ALBUTEROL SULFATE syrup United States - English - NLM (National Library of Medicine)

albuterol sulfate syrup

carilion materials management - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2 mg in 5 ml - albuterol sulfate syrup is indicated for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease. albuterol sulfate syrup is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components.

ALBUTEROL SULFATE solution United States - English - NLM (National Library of Medicine)

albuterol sulfate solution

bausch & lomb incorporated - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - solution - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm. albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components. albuterol sulfate inhalation solution, 0.5%* *potency expressed as albuterol read complete instructions carefully before using. 1. draw the appropriate volume of albuterol sulfate inhalation solution, 0.5% into the specially marked dropper that comes with each multidose bottle. for children 12 years of age and under, the volume is based upon body weight. use the dropper volume prescribed by your doctor. 2. squeeze the solution into the nebulizer reservoir through the appropriate opening, taking care not to touch the tip of the dropper. 3. add sterile normal saline solution, as your doctor has directed. a general guideline for the amount of saline to add is: for children us

LEVALBUTEROL- levalbuterol hydrochloride solution United States - English - NLM (National Library of Medicine)

levalbuterol- levalbuterol hydrochloride solution

nucare pharmaceuticals,inc. - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol inhalation solution, usp is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution, usp is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. teratogenic effects: pregnancy category c. there are no adequate and well-controlled studies of levalbuterol inhalation solution, usp in pregnant women. because animal reproduction studies are not always predictive of human response, levalbuterol inhalation solution, usp should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reporte

LEVALBUTEROL- levalbuterol hydrochloride solution United States - English - NLM (National Library of Medicine)

levalbuterol- levalbuterol hydrochloride solution

burel pharmaceuticals, llc - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol inhalation solution, usp is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution, usp is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. risk summary there are no adequate and well-controlled studies of levalbuterol inhalation solution, usp in pregnant women. there are clinical considerations with the use of levalbuterol inhalation solution, usp in pregnant women [see clinical considerations] . following oral administration of levalbuterol hcl to pregnant rabbits, there was no evidence of teratogenicity at doses up to 25 mg/kg/day [approximately 108 times the maximum recommended human daily inhalation dose (mrhdid) of levalbuterol hcl for adults on a mg/m2 basis

LEVALBUTEROL- levalbuterol hydrochloride solution United States - English - NLM (National Library of Medicine)

levalbuterol- levalbuterol hydrochloride solution

bryant ranch prepack - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol inhalation solution, usp is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution, usp is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. teratogenic effects: pregnancy category c. there are no adequate and well-controlled studies of levalbuterol inhalation solution, usp in pregnant women. because animal reproduction studies are not always predictive of human response, levalbuterol inhalation solution, usp should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in newborns

LEVALBUTEROL- levalbuterol hydrochloride solution United States - English - NLM (National Library of Medicine)

levalbuterol- levalbuterol hydrochloride solution

bryant ranch prepack - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol inhalation solution, usp is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution, usp is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. teratogenic effects: pregnancy category c. there are no adequate and well-controlled studies of levalbuterol inhalation solution, usp in pregnant women. because animal reproduction studies are not always predictive of human response, levalbuterol inhalation solution, usp should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in newborns

LEVALBUTEROL- levalbuterol hydrochloride solution United States - English - NLM (National Library of Medicine)

levalbuterol- levalbuterol hydrochloride solution

bryant ranch prepack - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol inhalation solution, usp is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution, usp is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. teratogenic effects: pregnancy category c. there are no adequate and well-controlled studies of levalbuterol inhalation solution, usp in pregnant women. because animal reproduction studies are not always predictive of human response, levalbuterol inhalation solution, usp should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in newborns